Compare · BDX vs NYXH
BDX vs NYXH
Side-by-side comparison of Becton Dickinson and Company (BDX) and Nyxoah SA (NYXH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and NYXH operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $52.78B, about 443.2x NYXH ($119.1M).
- Over the past year, BDX is up 0.3% and NYXH is down 81.1% - BDX leads by 81.5 points.
- BDX has been more active in the news (8 items in the past 4 weeks vs 3 for NYXH).
- BDX has more recent analyst coverage (25 ratings vs 9 for NYXH).
- Company
- Becton Dickinson and Company
- Nyxoah SA
- Price
- $191.68-1.09%
- $1.13-5.44%
- Market cap
- $52.78B
- $119.1M
- 1M return
- +5.72%
- -24.16%
- 1Y return
- +0.32%
- -81.14%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 3
- Recent ratings
- 25
- 9
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Nyxoah SA
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest NYXH
- Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Appoints Liam Kelly as Chief Executive Officer
- SEC Form 6-K filed by Nyxoah SA
- CVRx Appoints John Landry as Chief Financial Officer
- Nyxoah Announces Chief Financial Officer Transition
- Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System
- Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients
- Information on the total number of voting rights and shares
- Amendment: SEC Form SCHEDULE 13G/A filed by Nyxoah SA